Clinical Trials Logo

Clinical Trial Summary

This study aims to determine if a short course of oral prednisone helps to improve the operative field and ease of surgery by minimizing bleeding during nasal polypectomy surgery.


Clinical Trial Description

This study will be conducted as a double blinded randomized control trial and aims to recruit about 34 patients (17 patients per arm). Patients will be randomized to receive either prednisone 50 mg po x10 days or an identical looking placebo x10 days. Photographs of the polyps will be taken prior to the intervention, on the day of surgery and in the follow-up visit. Symptom survey (SNOT22) will also be administered at these same time points. Blood loss will be determined volumetrically from the suction canister and by using the Wormald Surgical field grading scale. Surgeons will also complete a survey postoperatively evaluating visibility, difficulty and ease of surgery. At 2 weeks, 1 month, 3 months and 6 months, patients will again fill out the Sino-nasal Outcome Test - 22 (SNOT-22) and the surgeon will do an endoscopic assessment by using the Peri-Operative Sinus Endoscopy (POSE) scoring system . ;


Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT00440219
Study type Interventional
Source Samuel Lunenfeld Research Institute, Mount Sinai Hospital
Contact
Status Completed
Phase Phase 3
Start date November 2010
Completion date June 2013

See also
  Status Clinical Trial Phase
Withdrawn NCT02071667 - Association of Periostin Levels and Chronic Sinusitis N/A
Completed NCT01623310 - 12-Month OL Intranasal Fluticasone Propionate BID Using OptiNose Device Phase 3
Completed NCT02024659 - Effects and Safety of Budesonide Inhalation Suspension Via Transnasal Nebulization in Nasal Polyps Phase 2/Phase 3
Completed NCT00215787 - Investigation of the Association Between Nasal Polyposis and Extraesophageal Reflux Disease N/A
Completed NCT04996576 - Infrazygomatic Versus Intranasal Injection Sphinopalatine Ganglion Blockade Effect on Surgical Field in FESS N/A
Recruiting NCT03963648 - NO Measurements in Screening for Asthma and OSA, in Patients With CRSwNP N/A
Recruiting NCT05094570 - Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP Phase 4
Recruiting NCT05009758 - Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps N/A
Completed NCT00731185 - Mometasone Furoate Nasal Spray for Treatment of Nasal Polyposis After Surgery (Study P03218) Phase 3
Active, not recruiting NCT03943121 - The Effects of Steroid-eluting Stent Implant for the Treatment of Eosinophilic Chronic Rhinosinusitis With Nasal Polyps N/A
Active, not recruiting NCT03704415 - Aggravated Airway Inflammation: Research on Genomics and Optimal Operative Treatment (AirGOs Operative) N/A
Not yet recruiting NCT06070311 - Wound Healing After Endoscopic Sinus Surgery N/A
Completed NCT02879929 - Development and Validity of the DyNaChron Questionnaire for Chronic Nasal Dysfunction N/A
Recruiting NCT05672030 - Role of IL-5R Signaling in Non-eosinophil Upper Airway Cells in CRSwNP
Suspended NCT04261582 - Genetics and Genomics of Aspirin Exacerbated Respiratory Disease (AERD)
Recruiting NCT05063981 - Treatment With Mepolizumab on Patients With Severe Refractory Eosinophilic Asthma With or Without CRSwNP.
Completed NCT05180357 - RANS. Study in Patients With Severe Eosinophilic Asthma and Nasal Polyps.
Completed NCT00788463 - A Comparison of Beclomethasone Aqueous Spray and Aerosol Delivery Systems in Nasal Polyps Phase 2
Completed NCT01198912 - Influence of Oral Doxycycline on Wound Healing After Endonasal Endoscopic Sinus Surgery for Chronic Rhinosinusitis With and Without Nasal Polyposis: a Double-blind Randomized Placebo-controlled Trial Phase 2
Completed NCT03280537 - A Clinical Trial of Omalizumab in Participants With Chronic Rhinosinusitus With Nasal Polyps Phase 3